Gene therapy for rare blindness shows promise in Long-Term study

NCT ID NCT03406104

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times

Summary

This study followed 62 people with Leber Hereditary Optic Neuropathy (LHON) who received GS010 gene therapy in earlier trials. Researchers tracked eye safety and vision changes for up to 5 years after treatment. The goal was to see if the therapy remains safe and helps maintain or improve eyesight over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEBER HEREDITARY OPTIC NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHNO Les Quinze Vingts

    Paris, 75012, France

  • Doheny Eye Center UCLA

    Pasadena, California, 91105, United States

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • LMU Klinikum der Universität München / Friedrich-Baur-Institut

    Munich, 80336, Germany

  • Moorfields Eye Hospital

    London, Greater London, EC1V 2PD, United Kingdom

  • Ospedale Bellaria

    Bologna, 40139, Italy

  • Wills Eye Institute

    Philadelphia, Pennsylvania, 19107, United States

Conditions

Explore the condition pages connected to this study.